SAMe
Content by: OpenSupplement Editorial Team | Medical review: pending | Last updated: April 13, 2026
TL;DR
Universal methyl donor participating in over 200 metabolic reactions throughout the body
Prescription drug in Europe with strong evidence for liver disease and depression
Works by directly providing methyl groups for DNA methylation, neurotransmitter synthesis, and detoxification
Well-tolerated but can trigger mania in bipolar disorder — avoid if bipolar
Monthly cost $30-60 for quality enteric-coated forms
Best for: liver disease, depression (as adjunct), methylation support
What it is
S-Adenosyl-L-Methionine (SAMe) is a naturally occurring compound found in every cell of the body, serving as the primary methyl donor for over 200 biochemical reactions. Unlike many supplements that work indirectly, SAMe directly participates in essential processes including DNA methylation, neurotransmitter synthesis, and liver detoxification pathways.
SAMe's clinical credibility stems from its prescription drug status across Europe, where it's approved for treating depression and liver disease. The compound works by donating methyl groups (-CH₃) to other molecules, a process called methylation that's crucial for gene expression, neurotransmitter production, and cellular repair. It also supports glutathione synthesis — the body's master antioxidant — making it particularly valuable for liver health.
What the research says
Prescription-grade liver support — SAMe holds prescription drug status in Europe specifically for liver disease, backed by decades of clinical research. The landmark Frezza study [1] demonstrated significant improvement in intrahepatic cholestasis of pregnancy, while the comprehensive Mato trial [2] showed improved survival rates in patients with alcoholic liver cirrhosis.
Glutathione pathway support — SAMe directly participates in the transsulfuration pathway that produces glutathione, the liver's primary detoxification compound. The Anstee review [4] emphasizes this mechanism as key to SAMe's hepatoprotective effects. Unlike antioxidants that work after damage occurs, SAMe helps prevent liver damage by supporting the cellular machinery responsible for detoxification.
Clinical recommendation: For liver support, use 400-1200 mg daily of enteric-coated SAMe, preferably the butanedisulfonate form used in European studies. Take on empty stomach for best absorption. Consider testing homocysteine levels to monitor methylation status.
Depression-focused evidence — The Papakostas meta-analysis [3] confirms SAMe's antidepressant effects, but direct cognitive decline research remains limited. Most cognitive benefits appear secondary to mood improvement rather than primary neuroprotective effects.
Methylation and brain health — Theoretically compelling given SAMe's role in neurotransmitter synthesis and DNA methylation in brain tissue. However, this hasn't translated to robust clinical evidence for cognitive decline prevention or treatment.
Current recommendation: Consider SAMe for cognitive concerns only if depression is also present. The evidence for pure cognitive enhancement or dementia prevention remains insufficient to recommend it as a primary cognitive supplement.
DISCLAIMER: The information on this page is for educational purposes only and has not been evaluated by the Food and Drug Administration. This content is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before using any dietary supplement, especially if you are pregnant, nursing, taking medication, or have a medical condition.
This page may contain affiliate links. If you purchase through these links, we may earn a small commission at no extra cost to you. Learn more.
SAMe on Amazon
Safety
SAMe is generally well-tolerated with most side effects being mild gastrointestinal symptoms including nausea, stomach upset, and diarrhea. Some users experience anxiety or insomnia, particularly at higher doses or when taken later in the day.
Critical warning for bipolar disorder — SAMe can trigger manic episodes in individuals with bipolar disorder and should be completely avoided in this population. Always screen for bipolar history before starting SAMe, as the risk of mania is well-documented and potentially dangerous.
Interactions
• SSRIs and SNRIs — Moderate risk of serotonin syndrome when combined with selective serotonin reuptake inhibitors • MAOIs — Significant interaction risk; do not combine with monoamine oxidase inhibitors • Levodopa — May reduce effectiveness of Parkinson's medications containing levodopa • Tramadol and triptans — Minor to moderate risk of serotonergic effects • St. John's Wort — Avoid combination due to additive serotonergic effects
Dosing
For liver support: 400-1200 mg daily of enteric-coated SAMe butanedisulfonate, divided into 2-3 doses. Take on empty stomach, 30 minutes before meals.
For mood support: 400-800 mg daily, starting with 200 mg twice daily and increasing gradually. Begin with morning doses to avoid sleep disruption.
Form matters significantly — Choose enteric-coated tablets to prevent stomach acid degradation. The butanedisulfonate form used in European prescription formulations shows superior stability and absorption compared to tosylate forms.
Cost
Expect $30-60 monthly for quality enteric-coated SAMe from reputable manufacturers. European pharmaceutical-grade brands command premium prices ($50-80) but offer superior stability and potency. Generic versions are available but quality varies significantly — this is one supplement where brand reputation matters for both stability and absorption.
The bottom line
SAMe represents one of the few supplements with prescription drug credibility, particularly for liver disease where European approval provides strong validation. The evidence for liver support is genuinely impressive, while depression benefits are well-established though it works best as adjunctive therapy. However, avoid entirely if you have bipolar disorder, and be cautious about drug interactions. For liver health specifically, SAMe offers prescription-grade benefits in supplement form — just expect to pay accordingly for quality formulations.
References
- Frezza M, Centini G, Cammareri G, et al. S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepatogastroenterology. 1990;37(2):122-5.
- Mato JM, Cámara J, Fernández de Paz J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30(6):1081-9.
- Papakostas GI, Mischoulon D, Shyu I, et al. S-adenosyl methionine (SAMe) for depression: a systematic review and meta-analysis. J Clin Psychiatry. 2010;71(7):905-13.
- Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol. 2012;57(5):1097-109.
Sources for this page include published meta-analyses, systematic reviews, and NIH dietary supplement fact sheets. All claims reflect the evidence as of early 2026.
This is not medical advice. Consult your healthcare provider before starting any supplement, especially if you take medications.